Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Optic Atrophy Management Market Snapshot (2023 to 2033)

The global optic atrophy management market is expected to reach a valuation of US$ 8 billion in 2023 and is projected to exhibit a CAGR of 4.9% from 2023 to 2033. By the end of the aforementioned forecast period, the market is likely to close at US$ 15.63 billion.

An existing medical analysis in gene replacement therapy has shown a satisfactory safety record but poor durability of medicinal outcomes. The research findings are encouraging and a superior comprehension of the pathophysiology of neuropathies ought to and will facilitate the creation of prospective viable strategies for vision preservation. Therefore, it will result in high growth of the optic atrophy management market.

The progression of atrophy is incremental. According to a report published on Bookinghealth.com, the disease causes irreversible blindness in 21% of cases and disability in 68% of cases. It is estimated that 1 in 35,000 people globally suffers from optic atrophy type 1. Based on a study published by the optography organization, this disease is more prevalent in Denmark, where it impacts approximately 1 in 10,000 people.

The higher incidence of optic nerve atrophy will serve as a key driver, resulting in the growing market. The soaring healthcare spending is just another significant influence on the pace of growth of the optic nerve atrophy treatment market. Moreover, advancements in medical technology, rising activities by individuals and organizations to raise awareness, and increased federal funding will all aid the expansion of the optic nerve atrophy treatment market. Other factors including the increasing geriatric population and increased demand for effective therapies will boost the growth rate of the optic atrophy treatment market. Furthermore, rising disposable income and an increase in the incidences of diabetes, glaucoma, and brain tumors will stimulate the development of the optic nerve atrophy treatment market.

The global amebicide drugs segment is being influenced by the increasing pervasiveness of parasitic infections throughout the world. The growing number of individuals afflicted by amebic infections and the high cost of new drugs in addition to the high cost of new drugs is expected to dramatically boost this market over the next several years. The segment under the distribution channel the hospital pharmacies segment held the largest share of the market in 2021. Moreover, the same segment is expected to register the highest CAGR from 2023 to 2033.

As a result of a large number of prominent stakeholders, significant disposable income, and well-developed sophisticated healthcare in this region, North America leads the optic atrophy management market. Asia-Pacific is estimated to increase over the forecast period of 2023-2033 owing to high prevalence rates, rising medical expenditure, and increased government subsidies. The progression of atrophy is incremental. According to a report published on Bookinghealth.com, the condition causes irreversible blindness in 21% of instances and disability in 68% of cases. As a result, stem cell treatment for optic atrophy is gaining popularity in Germany, therefore, it is contributing to market expansion in Europe. Considering the aforementioned facts and figures, the market is projected to exhibit a good rate of growth.

Report Attribute Details
Expected Market Value (2023) US$ 8 Billion
Anticipated Forecast Value (2033) US$ 15.63 Billion
Projected Growth Rate (2023 to 2033) 4.9% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Optic Atrophy Management Demand Analysis vs. Forecast 2023 to 2033

Due to the lack of these drugs in many developed nations, the popularity of optic atrophy management has introduced enormous possibilities for the producers of COVID-19 managerial drugs. As a result of the demand for COVID-19 vaccines and treatment drugs, the bio and pharmaceutical industries are predicted to expand significantly in the coming years. As a result, the worldwide market is expected to suffer significantly.

Theglobal demand for Optic Atrophy Management is projected to increase at a CAGR of 4.9% during the forecast period between 2023 and 2033, reaching a total of US$ 15.63 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3%.

Which are Some Prominent Drivers of the Optic Atrophy Management Market?

Rise in Prevalence of Cardiac Aneurysm to Push the Market Growth

One of the crucial factors propelling the expansion of the optic atrophy management market is the higher incidence of multiple sclerosis (MS) patients. As a result, companies are boosting manufacturing capacity in order to develop products that improve patients’quality of life.

In September 2019, for instance, the Swiss multinational healthcare company Roche disclosed the findings of trials for OCREVUS, an immunosuppressive drug, to better understand its impacts on recurring and gradual MS.

Advanced Drug Design and Manufacturing Capacity to boost the Market Growth

With the aid of enhanced drugformulations, firms that sell drugs for the treatment of optic atrophy treatmenthope to minimizeprecorneal drug loss and maximizedrug delivery to the anterior cells. They are incorporating mucoadhesive formulas into the creation of new drugs in the hopes of increasing ocular penetration.

Drug-particle reduced size strategies, for instance, permit faster solubilization, increasing bioavailability and permeation. As a result, companies in the optic atrophy treatment market are increasing their advanced drug design manufacturing capacity.

What are the Challenges Projected to be Faced by the Market?

High Costs to Hinder Market Growth

The high costs incurred in the study and advancement of pipeline applicants used for the diagnosis of rare conditions may stymie market growth, resulting in an increase in drug prices.

This can be credited to factors like increased capital for contract research organizations(CROs) undertaking clinical studies and the risk of drug rejection during clinical testing.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Region-Wise Insights

What Makes North America the Largest Market for Optic Atrophy Management?

North America to dominate the market

North America is expected to have the largest market share during the forecast period. In 2021, the region had the largest market share. Increasing population acknowledgment of optical neuritis and MS, an aging population, and well-established sophisticated healthcare in North America are among the variables influencing growth prospects.

According to a current article published in the Journal of Neurology, the yearly recurrence of optic neuritis in the United States is associated with 5/1,000,000, with an estimated prevalence of 115/1,000,000. Increasing awareness about the early diagnosis of optic neuritis caused by multiple sclerosis and the availability of low-cost treatment options are expected to drive the global optic atrophy management market over the forecast period.

Why is Europe Considered a Lucrative Region for the Optic Atrophy Management Market?

Aging population in Europe drives the market growth

Furthermore, Europe is expected to grow significantly and become the world's second-largest market in terms of revenue in the market. Stem cell therapy is being researched extensively as an intervention for degenerative eye diseases; it intends to replace dead neurons and restore nerve components. One medical study in Switzerland illustrated stem cell ef?cacy in nerve damage.

Clinical studies were also conducted at prestigious medical institutions in Germany, Switzerland, and Belgium. In 70-90% of scenarios, a positive therapeutic effect was noticed in the form of enhanced motor and sensory activities. As a result, the high demand for stem cell therapy in Germany is expected to fuel market growth.

Ischemic optic neuropathy is an ailment in which there is an absence of blood flow to the optic nerve, resulting in sudden visual impairment. People over the age of 50 are more likely to develop ischemic optic neuropathy. As a result, Europe's growing geriatric population is also cruising the regional market. As per Statista's 2021 data, Europe has the highest proportion of older people (19%).

Category-Wise Insights

Which Type Leads the Market for Optic Atrophy Management?

Increased prevalence of eye diseases to drive sales growth

The rise in the pervasiveness of eye disorders, as well as the rise in the aging populations, who are more likely to be affected by these eye diseases, are expected to boost demand for chloramphenicol eye drops. Furthermore, increased recognition of the significance of eye care contributes to market expansion.

Moreover, the segment's expansion is aided by the easy accessibility and affordability of lubricating eye drops, in addition to drug research and advancement in vision care products. In 2021, the specialty pharmacy segment ruled the industry with a profit share of more than 64.9%. The prominence can be credited to important players' strategic planning, for instance, the acquirement of specialty pharmacies for the delivery of their products.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Market Competition

Key players in the Optic Atrophy Management market are AbbVie Inc, Eli Lily Company, GlaxoSmithKline, Pfizer Inc, Teva Pharmaceuticals, F. Hoffmann-La Roche AG, Bayer AG, Sanofi A.S., Bristol-Myers Squibb and Company, Bausch Health Companies Inc. Some of the latest developments by key players are below

  • Pfizer agreed to purchase Biohaven Pharmaceutical Holding Company, a clinical-stage biotechnology company, in May 2022. Given the company's major scale and capabilities, including conducted field force involvement with Primary Healthcare Physicians, professionals, and hospital systems supplying the correct data at the appropriate time, Pfizer would be uniquely placed to assist the portfolio to reach its maximum potential through this acquirement.
  • Pfizer partnered with AbbVie, an American publicly listed Biopharmaceutical Corporation, in July 2021. Pfizer would regularly evaluate how medical application data at this enormous scale is best utilized through the acquisition, aiming to ramp up the route from genetic discoveries to new therapeutics.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 8 billion
Market Value in 2033 US$ 15.63 billion
Growth Rate CAGR of 4.9% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Drug Type
  • Route of Administration
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • AbbVie Inc.
  • Eli Lily & Company
  • GSK plc.
  • Pfizer Inc.
  • Teva Pharmaceuticals
  • F. Hoffmann-La Roche AG
  • Bayer AG
  • Sanofi SA
  • Bristol-Myers Squibb Company
  • Bausch Health Companies Inc.
Customization Available Upon Request

Key Segments Profiled in the Optic Atrophy Management Market Survey 

By Drug Type:

  • Disulfiram
  • Amebicides
  • Ethambutol
  • Isoniazid
  • Chloramphenicol
  • Vincristine
  • Ciclosporin
  • Cimetidine

By Route of Administration:

  • Oral
  • Injectable

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Latin America
  • Middle East and Africa (MEA)

Frequently Asked Questions

What Factors Influencing the Market in the United States?

Early diagnosis of optic neuritis and low-treatment cost influence the market growth.

Which Country is Set to Register Exponential Growth in the Market?

The United States and Germany may witness significant growth in the market.

What Drives Sales of Optic Atrophy Management?

Well-established treatments are expected to drive sales.

What Key Trends are Driving the Optic Atrophy Management Market?

Aging population may drive market growth over the coming years.

How was the Historical Performance of the Optic Atrophy Management Market?

The market recorded a CAGR of 3% in 2022.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033

        5.3.1. Disulfiram

        5.3.2. Amebicides

        5.3.3. Ethambutol

        5.3.4. Isoniazid

        5.3.5. Chloramphenicol

        5.3.6. Vincristine

        5.3.7. Ciclosporin

        5.3.8. Cimetidine

    5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        6.3.1. Oral

        6.3.2. Injectable

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. United States

            9.2.1.2. Canada

        9.2.2. By Drug Type

        9.2.3. By Route of Administration

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Type

        9.3.3. By Route of Administration

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Type

        10.2.3. By Route of Administration

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Type

        10.3.3. By Route of Administration

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom.

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Drug Type

        11.2.3. By Route of Administration

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Type

        11.3.3. By Route of Administration

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Drug Type

        12.2.3. By Route of Administration

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Type

        12.3.3. By Route of Administration

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Drug Type

        13.2.3. By Route of Administration

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Type

        13.3.3. By Route of Administration

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Drug Type

        14.2.3. By Route of Administration

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Type

        14.3.3. By Route of Administration

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Drug Type

        15.2.3. By Route of Administration

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Type

        15.3.3. By Route of Administration

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Drug Type

            16.1.2.2. By Route of Administration

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Drug Type

            16.2.2.2. By Route of Administration

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Drug Type

            16.3.2.2. By Route of Administration

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Drug Type

            16.4.2.2. By Route of Administration

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Drug Type

            16.5.2.2. By Route of Administration

            16.5.2.3. By Distribution Channel

    16.6. United kingdom

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Drug Type

            16.6.2.2. By Route of Administration

            16.6.2.3. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Drug Type

            16.7.2.2. By Route of Administration

            16.7.2.3. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Drug Type

            16.8.2.2. By Route of Administration

            16.8.2.3. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Drug Type

            16.9.2.2. By Route of Administration

            16.9.2.3. By Distribution Channel

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Drug Type

            16.10.2.2. By Route of Administration

            16.10.2.3. By Distribution Channel

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Drug Type

            16.11.2.2. By Route of Administration

            16.11.2.3. By Distribution Channel

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Drug Type

            16.12.2.2. By Route of Administration

            16.12.2.3. By Distribution Channel

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Drug Type

            16.13.2.2. By Route of Administration

            16.13.2.3. By Distribution Channel

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Drug Type

            16.14.2.2. By Route of Administration

            16.14.2.3. By Distribution Channel

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Drug Type

            16.15.2.2. By Route of Administration

            16.15.2.3. By Distribution Channel

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Drug Type

            16.16.2.2. By Route of Administration

            16.16.2.3. By Distribution Channel

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Drug Type

            16.17.2.2. By Route of Administration

            16.17.2.3. By Distribution Channel

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Drug Type

            16.18.2.2. By Route of Administration

            16.18.2.3. By Distribution Channel

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Drug Type

            16.19.2.2. By Route of Administration

            16.19.2.3. By Distribution Channel

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Drug Type

            16.20.2.2. By Route of Administration

            16.20.2.3. By Distribution Channel

    16.21. Israel

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Drug Type

            16.21.2.2. By Route of Administration

            16.21.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Drug Type

        17.3.3. By Route of Administration

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. AbbVie Inc.

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Eli Lily Company

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. GlaxoSmithKline

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Pfizer Inc.

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Teva Pharmaceuticals

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. F. Hoffmann-La Roche AG

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Bayer AG

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Sanofi A.S.

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Bristol-Myers Squibb and Company

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Bausch Health Companies Inc.

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Ophthalmic Eye Drop Market

Published : March 2024

Healthcare

Multiple System Atrophy (MSA) Therapeutics Market

Published : December 2022

Healthcare

Ophthalmic Lasers Market

Published : June 2022

Explore Healthcare Insights

View Reports

Optic Atrophy Management Market